Subject(s)

Antiviral Agents/adverse effects , Coronavirus Infections/drug therapy , Cytokine Release Syndrome/prevention & control , Drug Hypersensitivity/etiology , Immunologic Factors/adverse effects , Pneumonia, Viral/drug therapy , Adenosine Monophosphate/administration & dosage , Adenosine Monophosphate/adverse effects , Adenosine Monophosphate/analogs & derivatives , Adrenal Cortex Hormones/therapeutic use , Alanine/administration & dosage , Alanine/adverse effects , Alanine/analogs & derivatives , Amides/administration & dosage , Amides/adverse effects , Antibodies, Monoclonal, Humanized/administration & dosage , Antibodies, Monoclonal, Humanized/adverse effects , Antiviral Agents/administration & dosage , Betacoronavirus/drug effects , Betacoronavirus/immunology , Betacoronavirus/pathogenicity , COVID-19 , Coronavirus Infections/immunology , Coronavirus Infections/virology , Cytokine Release Syndrome/immunology , Cytokine Release Syndrome/virology , Drug Hypersensitivity/diagnosis , Drug Hypersensitivity/drug therapy , Drug Hypersensitivity/immunology , Humans , Immunity, Innate/drug effects , Immunologic Factors/administration & dosage , Indoles/administration & dosage , Indoles/adverse effects , Infliximab/administration & dosage , Infliximab/adverse effects , Interleukin 1 Receptor Antagonist Protein/administration & dosage , Interleukin 1 Receptor Antagonist Protein/adverse effects , Nitriles , Pandemics , Pneumonia, Viral/immunology , Pneumonia, Viral/virology , Pyrazines/administration & dosage , Pyrazines/adverse effects , Pyrazoles/administration & dosage , Pyrazoles/adverse effects , Pyrimidines , SARS-CoV-2 , Severity of Illness Index